Back to Agenda
Session 2 -Submission Predictability in Initial Marketing Authorisation: An Industry Perspective
Session Chair(s)
Aimad Torqui
Head of Division European cooperation and veterinary affairs
MEB, Netherlands
This session examines submission predictability from the industry's perspective, highlighting the challenges and uncertainties faced during the development of a Global Submission. It will illustrate effective case studies where submission dates were adjusted while keeping all key stakeholders and regulators informed in advance. Drawing on available insights & learnings and guidance, the industry will share best practices for planning a submission, strengthening dialogue with regulators and improving predictability of submissions for all stakeholders.
Speaker(s)
Industry representatives’ viewpoints & learnings on submission predictability
Pedro Franco, PharmD, PhD, MS, MSc
Merck Serono Limited, United Kingdom
Senior Director for Global Regulatory & Scientific Policy (GRASP)
Cases studies on submission predictability
Stefan Schwoch, PhD, RPh
Eli Lilly and Company Limited, United Kingdom
VP Global Regulatory Affairs EMEA
Rebecca Lumsden, PhD
Sanofi, United Kingdom
Head of Regulatory Science & Policy EU/AMEE
Have an account?
